Disease, destination, dose and delivery aspects of ciclosporin: the state of the art.
about
Novel formulations for antimicrobial peptidesMicro and nanoparticle drug delivery systems for preventing allotransplant rejectionPorous magnesium aluminometasilicate tablets as carrier of a cyclosporine self-emulsifying formulation.Ultrasound-promoted synthesis and immunosuppressive activity of novel quinazoline derivatives.Inhibitory actions of HERG currents by the immunosuppressant drug cyclosporin a.Immunosuppressive Activity of Size-Controlled PEG-PLGA Nanoparticles Containing Encapsulated Cyclosporine ALipid nanoparticles for cyclosporine A administration: development, characterization, and in vitro evaluation of their immunosuppression activity.Preparation and in vitro and in vivo characterization of cyclosporin A-loaded, PEGylated chitosan-modified, lipid-based nanoparticles.Polymeric nanoparticle drug delivery technologies for oral delivery applications.Applications of nanoparticles in the detection and treatment of kidney diseasesOral cyclosporine A--the current picture of its liposomal and other delivery systems.Enhancement of physicochemical properties of nanocolloidal carrier loaded with cyclosporine for topical treatment of psoriasis: in vitro diffusion and in vivo hydrating action.Malignant tumor-like gastric lesion due to Candida albicans in a diabetic patient treated with cyclosporin: a case report and review of the literature.A new approach to the treatment of recurrent aphthous stomatitis with bioadhesive gels containing cyclosporine A solid lipid nanoparticles: in vivo/in vitro examinations.Interpretation of tandem mass spectra obtained from cyclic nonribosomal peptides.Nanoparticles made of multi-block copolymer of lactic acid and ethylene glycol containing periodic side-chain carboxyl groups for oral delivery of cyclosporine A.The immunosuppressive activity of polymeric micellar formulation of cyclosporine A: in vitro and in vivo studiesSpectral and spatial characterization of protein loaded PLGA nanoparticles.Nanotechnological Approaches to Immunosuppression and Tolerance Induction.Use of episcleral cyclosporine implants in dogs with keratoconjunctivitis sicca: pilot study.Cyclosporine A-Loaded Solid Lipid Nanoparticles: Ocular Tolerance andIn VivoDrug Release in Rabbit Eyes
P2860
Q26991771-AB64A29A-DB0D-4D27-A95D-B6A0E08F627DQ28080720-B470FCCC-E9FB-4750-AB52-3E826A204CAAQ33563592-65E3736D-A80F-414C-B8DD-BCAC79D40A12Q34379063-5B3CBE48-121B-4DDA-8B51-B49FE522058BQ35569365-7842E44C-194C-4A28-9307-0D30561219C9Q35876168-62735EDD-6249-433D-BCEC-2A072DA9C6A8Q36208560-C0FC542D-3995-4C55-86C3-21C470F308FCQ36617869-C17B06D7-9E41-49FF-A5F0-0FE41CCD3C5AQ36808308-E7413C0C-9AF2-458D-B3A2-03E380469C8AQ37298541-518C25C9-95B2-4E22-9C8B-951531CE3C07Q37324276-3E2B8C4A-4A36-42A8-AFF1-96D97BF3A10EQ37735794-057C472D-560F-4BE9-A649-8FB0A0407BD0Q37929630-2D1D3E24-A996-462B-9AEF-B1FC434A5378Q41159576-FE3104AA-C269-44F9-A6CE-A807A6CDD1B6Q41889971-5F8B39DD-4611-4351-B369-C77F1C939F19Q42422945-D56BFB57-F0EA-476B-9263-81AB430BAE5DQ42725258-0C285C78-1541-486E-940F-AB3BC9704F08Q42728592-AD42545B-4B3D-466D-A33D-EB78E884E17BQ50066247-F08F0682-AC58-4BFB-90AF-9BB16CA4FFABQ53558849-B2845306-F5D5-42BF-8482-585C05190CC4Q59155923-18618C01-3C70-4550-B08A-7CA765AAA99F
P2860
Disease, destination, dose and delivery aspects of ciclosporin: the state of the art.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Disease, destination, dose and delivery aspects of ciclosporin: the state of the art.
@ast
Disease, destination, dose and delivery aspects of ciclosporin: the state of the art.
@en
type
label
Disease, destination, dose and delivery aspects of ciclosporin: the state of the art.
@ast
Disease, destination, dose and delivery aspects of ciclosporin: the state of the art.
@en
prefLabel
Disease, destination, dose and delivery aspects of ciclosporin: the state of the art.
@ast
Disease, destination, dose and delivery aspects of ciclosporin: the state of the art.
@en
P2093
P1433
P1476
Disease, destination, dose and delivery aspects of ciclosporin: the state of the art.
@en
P2093
Jagdish L Italia
M N V Ravi Kumar
Vivekanand Bhardwaj
P304
P356
10.1016/J.DRUDIS.2006.07.015
P577
2006-09-01T00:00:00Z